Baricitinib-induced paradoxical psoriasis.
Fiche publication
Date publication
février 2020
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François
Tous les auteurs :
Di Domizio J, Castagna J, Algros MP, Prati C, Conrad C, Gilliet M, Wendling D, Aubin F
Lien Pubmed
Résumé
Although recent drugs including biological agents and small molecules targeting key inflammatory mediators have revolutionized the management of different chronic inflammatory diseases, these treatments lead to the development of psoriasis-like skin lesions in 2-5% of treated patients called paradoxical psoriasis. Here we report the first case of paradoxical psoriasis induced by baricitinib, a novel janus kinase (JAK) 1/2 inhibitor.
Mots clés
JAK inhibitor, adverse event, baricitinib, psoriasis
Référence
J Eur Acad Dermatol Venereol. 2020 Feb 13;: